These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
182 related articles for article (PubMed ID: 1078714)
1. New approaches to cancer chemotherapy with methotrexate. Frei E; Jaffe N; Tattersall MH; Pitman S; Parker L N Engl J Med; 1975 Apr; 292(16):846-51. PubMed ID: 1078714 [No Abstract] [Full Text] [Related]
2. Methotrexate revisited. Frei E Med Pediatr Oncol; 1976; 2(3):227-41. PubMed ID: 790144 [No Abstract] [Full Text] [Related]
3. High-dose methotrexate therapy with citrovorum factor: a pharmacologic perspective in murine tumor models. Sirotnak FM; Donsbach RC; Dorick DM; Moccio DM Cancer Treat Rep; 1977 Jul; 61(4):565-74. PubMed ID: 301778 [No Abstract] [Full Text] [Related]
4. "Rescue" techniques in cancer chemotherapy: use of leucovorin and other rescue agents after methotrexate treatment. Bertino JR Semin Oncol; 1977 Jun; 4(2):203-16. PubMed ID: 301662 [No Abstract] [Full Text] [Related]
5. Cytokinetic comparison of thymidine and leucovorin rescue of marrow in humans after exposure to high-dose methotrexate. Howell SB; Krishan A; Frei E Cancer Res; 1979 Apr; 39(4):1315-20. PubMed ID: 311245 [TBL] [Abstract][Full Text] [Related]
6. Clinical trials and pharmacokinetics of intermittent high-dose methotrexate-"leucovorin rescue" for children with malignant tumors. Pratt CB; Roberts D; Shanks EC; Warmath EL Cancer Res; 1974 Dec; 34(12):3326-31. PubMed ID: 4547680 [No Abstract] [Full Text] [Related]
7. Potentiation of the antitumor activity of methotrexate by concurrent infusion of thymidine. Semon JH; Grindey GB Cancer Res; 1978 Sep; 38(9):2905-11. PubMed ID: 679199 [No Abstract] [Full Text] [Related]
9. Optimization of high-dose methotrexate with leucovorin rescue therapy in the L1210 leukemia and sarcoma 180 murine tumor models. Sirotnak FM; Moccio DM; Dorick DM Cancer Res; 1978 Feb; 38(2):345-53. PubMed ID: 304375 [TBL] [Abstract][Full Text] [Related]
10. The reversal of methotrexate toxicity by thymidine with maintenance of antitumour effects. Tattersall MH; Brown B; Frei E Nature; 1975 Jan; 253(5488):198-200. PubMed ID: 1078601 [No Abstract] [Full Text] [Related]
11. New approaches to chemotherapy with folate antagonists: use of leucovorin "rescue" and enzymic folate depletion. Bertino JR; Levitt M; McCullough JL; Chabner B Ann N Y Acad Sci; 1971 Nov; 186():486-95. PubMed ID: 4943812 [No Abstract] [Full Text] [Related]
12. High-dose methotrexate with citrovorum factor in osteogenic sarcoma--progress report II. Jaffe N; Frei E; Traggis D; Cassady JR; Watts H; Filler RM Cancer Treat Rep; 1977 Jul; 61(4):675-9. PubMed ID: 301780 [TBL] [Abstract][Full Text] [Related]
13. Use of plasma pharmacokinetics to predict and prevent methotrexate toxicity. Stoller RG; Hande KR; Jacobs SA; Rosenberg SA; Chabner BA N Engl J Med; 1977 Sep; 297(12):630-4. PubMed ID: 302412 [TBL] [Abstract][Full Text] [Related]
14. High-dose methotrexate in osteogenic sarcoma: a 5-year experience. Jaffe N; Frei E; Watts H; Traggis D Cancer Treat Rep; 1978 Feb; 62(2):259-64. PubMed ID: 346215 [No Abstract] [Full Text] [Related]
15. Osteogenic sarcoma studies by the Cancer and Leukemia Group B. Cortes EP; Holland JF; Glidewell O Natl Cancer Inst Monogr; 1981 Apr; (56):207-9. PubMed ID: 7029290 [No Abstract] [Full Text] [Related]
16. Favorable response of metastatic osteogenic sarcoma to pulse high-dose methotrexate with citrovorum rescue and radiation therapy. Jaffe N; Paed D; Farber S; Traggis D; Geiser C; Kim BS; Das L; Frauenberger G; Djerassi I; Cassady JR Cancer; 1973 Jun; 31(6):1367-73. PubMed ID: 4541163 [No Abstract] [Full Text] [Related]